Literature DB >> 3613527

Immunohistochemical localization of the epithelial marker MAM-6 in invasive malignancies and highly dysplastic adenomas of the large intestine.

S Zotter, A Lossnitzer, P C Hageman, J F Delemarre, J Hilkens, J Hilgers.   

Abstract

MAM-6 antigen is detectable in a large variety of formalin fixed and paraffin embedded normal and neoplastic tissues throughout the body with some exceptions. One such exception is the large intestine in which normal mucosa has been found negative for MAM-6, while colorectal carcinomas express the antigen in almost all cases. We examined the expression of MAM-6 in 147 benign epithelial tumors (adenomas) of the colorectum and compared this with the detectability of the antigen in 123 colorectal cancers and in 108 non-neoplastic mucosa specimens. The tissue samples were subjected to an indirect immunoperoxidase assay applying the MoAb 115D8 which recognizes the epitope "a" of MAM-6. A majority of the carcinomas (99.2%) and of the adenomas (61.4%) exhibited reactivity for MAM-6 "a", whereas only 8 of the 108 non-neoplastic biopsy specimens (= 7.4%) exhibited faint focal staining. In adenomas, positive reactions were only seen in highly dysplastic tissue areas, in part reflecting carcinomata in situ. The reactivity in four non-neoplastic tissue samples could be explained by shedding of the antigen from carcinomas into glandular structures of the mucosa. Two out of 32 cases exhibiting severe colitis were also focally positive. The detectability of MAM-6 "a" in routinely processed specimens from the large intestine is therefore considered as being closely associated with malignant and premalignant processes. According to a limited study with the antibodies 139H2 and 140C1, this holds true for two additional MAM-6 epitopes. MAM-6 might be considered as a marker of severe (premalignant) dysplasia in adenomas of the large intestine. Further studies are needed to clarify if there is a biological (possibly prognostic) difference between MAM-6 positive and negative high epithelial atypia in these adenomas.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3613527

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  10 in total

1.  Comparison between colorectal low- and high-grade mucinous adenocarcinoma with MUC1 and MUC5AC.

Authors:  Masayuki Onodera; Takashi Nishigami; Ikuko Torii; Ayuko Sato; Li-Hua Tao; Tatsuki R Kataoka; Reigetsu Yoshikawa; Tohru Tsujimura
Journal:  World J Gastrointest Oncol       Date:  2009-10-15

2.  Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer.

Authors:  Ann Willman Silk; Robert E Schoen; Douglas M Potter; Olivera J Finn
Journal:  Mol Immunol       Date:  2009-02-13       Impact factor: 4.407

3.  Detection of a mucin marker for the adenoma-carcinoma sequence inhuman colonic mucosa by monoclonal antibody AM-3.

Authors:  C Hanski; G Bornhoeft; N Topf; U Hermann; H Stein; E O Riecken
Journal:  J Clin Pathol       Date:  1990-05       Impact factor: 3.411

Review 4.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

5.  Significance of MUC1 and MUC2 mucin expression in colorectal cancer.

Authors:  Y Ajioka; L J Allison; J R Jass
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

6.  MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.

Authors:  Takashi Kimura; John R McKolanis; Lynda A Dzubinski; Kazi Islam; Douglas M Potter; Andres M Salazar; Robert E Schoen; Olivera J Finn
Journal:  Cancer Prev Res (Phila)       Date:  2012-12-17

Review 7.  MUC1 in carcinoma-host interactions.

Authors:  K Denda-Nagai; T Irimura
Journal:  Glycoconj J       Date:  2000 Jul-Sep       Impact factor: 3.009

8.  Three to Tango: MUC1 as a Ligand for Both E-Selectin and ICAM-1 in the Breast Cancer Metastatic Cascade.

Authors:  Yue Geng; Kimberly Yeh; Tait Takatani; Michael R King
Journal:  Front Oncol       Date:  2012-07-27       Impact factor: 6.244

9.  The adenoma-carcinoma sequence in the colorectum--early appearance of a hierarchy of small intestinal mucin antigen (SIMA) epitopes and correlation with malignant potential.

Authors:  S J Pilbrow; P J Hertzog; A W Linnane
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

10.  A novel monoclonal antibody specific for sialylated MUC1 mucin.

Authors:  M Yamamoto; V P Bhavanandan; S Nakamori; T Irimura
Journal:  Jpn J Cancer Res       Date:  1996-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.